-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical’s Rosuvastatin Calcium Tablets (5 mg) Approved
Category:
发布时间：2022-06-15
【概要描述】
Recently, the rosuvastatin calcium tablets (5 mg) developed by Shijiazhuang Sihua Pharmaceutical Co., Ltd. were granted a drug registration certificate by the National Medical Products Administration and are deemed to have passed the consistency evaluation.
Recently, Shijiazhuang Sihua Pharmaceutical Co., Ltd. obtained a drug registration certificate from the National Medical Products Administration for its rosuvastatin calcium tablets (5 mg), which is deemed to have passed the consistency evaluation. According to reports, rosuvastatin calcium tablets are primarily indicated for the treatment of primary hypercholesterolemia or mixed dyslipidemia.
Previously, Shijiazhuang Sihua Pharmaceutical’s rosuvastatin calcium tablets (10 mg) were approved by the National Medical Products Administration in 2020 and subsequently passed the evaluation of quality and therapeutic equivalence for generic drugs. The recent approval of rosuvastatin calcium tablets (5 mg) will further enhance the company’s product portfolio.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091